Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H1 2013

Feb 2013 Global Markets Direct Lymphoma100 Pages Price :
$ 2000

Global Markets Directs, \'Peripheral T-Cell Lymphomas (PTCL) Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Peripheral T-Cell Lymphomas (PTCL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral T-Cell Lymphomas (PTCL). 

Peripheral T-Cell Lymphomas (PTCL) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Peripheral T-Cell Lymphomas (PTCL).
  • A review of the Peripheral T-Cell Lymphomas (PTCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Peripheral T-Cell Lymphomas (PTCL) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Peripheral T-Cell Lymphomas (PTCL) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) 8
Peripheral T-Cell Lymphomas (PTCL) Therapeutics under Development by Companies 10
Peripheral T-Cell Lymphomas (PTCL) Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Products under Development by Companies 16
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Peripheral T-Cell Lymphomas (PTCL) Therapeutics Development 18
Kyowa Hakko Kirin Co., Ltd. 18
Seattle Genetics, Inc. 19
Emergent BioSolutions Inc. 20
ZIOPHARM Oncology, Inc. 21
Millennium Pharmaceuticals, Inc. 22
Eisai Co., Ltd. 23
Celgene Corporation 24
TopoTarget A/S 25
Spectrum Pharmaceuticals, Inc. 26
Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
navitoclax - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
alisertib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
brentuximab vedotin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
belinostat - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
mogamulizumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
darinaparsin - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
denileukin diftitox - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
pralatrexate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
zanolimumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
lenalidomide - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
romidepsin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
alefacept - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
brentuximab vedotin + [cyclophosphamide] + [doxorubicin] + [prednisone] - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 61
Doxorubicin + Vincristine + Cyclophosphamide + Prednisone + Alemtuzumab + Methotrexate + Cytarabine+ Dexamethasone - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 63
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Drug Profile Updates 64
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Discontinued Products 91
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Dormant Products 92
Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones 93
Featured News & Press Releases 93
Nov 15, 2012: Celgene\'s Istodax Receives CHMP Negative Opinion For Treatment Of Peripheral T-cell Lymphoma 93
Oct 15, 2012: Topotarget Obtains EU Orphan Drug Designation For Belinostat To Treat Peripheral T-cell Lymphoma 94
Sep 24, 2012: Spectrum Pharma Provides Update On Belinostat Registrational Trial For Treatment Of Relapsed/Refractory Peripheral T-Cell Lymphoma 94
Sep 21, 2012: Topotarget Announces Belinostat Meets Primary Endpoint In Pivotal Lymphoma Trial 95
Jul 20, 2012: Millennium And Takeda Announce Positive CHMP Opinion For Conditional Approval Of ADCETRIS In Europe 96
Jul 20, 2012: Celgene To Request Re-Examination Of CHMP Istodax Opinion 97
Apr 20, 2012: Allos Therapeutics Announces Outcome Of Request For Re-examination Of CHMP Opinion For FOLOTYN In Europe 97

Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 100
Disclaimer 100

List of Table


Number of Products Under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2013 8
Products under Development for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis, H1 2013 9
Number of Products under Development by Companies, H1 2013 11
Number of Products under Investigation by Universities/Institutes, H1 2013 12
Comparative Analysis by Late Stage Development, H1 2013 13
Comparative Analysis by Mid Clinical Stage Development, H1 2013 14
Comparative Analysis by Early Clinical Stage Development, H1 2013 15
Products under Development by Companies, H1 2013 16
Products under Investigation by Universities/Institutes, H1 2013 17
Kyowa Hakko Kirin Co., Ltd., H1 2013 18
Seattle Genetics, Inc., H1 2013 19
Emergent BioSolutions Inc., H1 2013 20
ZIOPHARM Oncology, Inc., H1 2013 21
Millennium Pharmaceuticals, Inc., H1 2013 22
Eisai Co., Ltd., H1 2013 23
Celgene Corporation, H1 2013 24
TopoTarget A/S, H1 2013 25
Spectrum Pharmaceuticals, Inc., H1 2013 26
Assessment by Monotherapy Products, H1 2013 27
Assessment by Combination Products, H1 2013 28
Assessment by Stage and Route of Administration, H1 2013 30
Assessment by Stage and Molecule Type, H1 2013 32
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Drug Profile Updates 64
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Discontinued Products 91
Peripheral T-Cell Lymphomas (PTCL) Therapeutics - Dormant Products 92

List of Chart


Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H1 2013 8
Products under Development for Peripheral T-Cell Lymphomas (PTCL) - Comparative Analysis, H1 2013 9
Products under Development by Companies, H1 2013 10
Products under Investigation by Universities/Institutes, H1 2013 12
Late Stage Products, H1 2013 13
Mid Clinical Stage Products, H1 2013 14
Early Clinical Stage Products, H1 2013 15
Assessment by Monotherapy Products, H1 2013 27
Assessment by Combination Products, H1 2013 28
Assessment by Route of Administration, H1 2013 29
Assessment by Stage and Route of Administration, H1 2013 30
Assessment by Molecule Type, H1 2013 31
Assessment by Stage and Molecule Type, H1 2013 32

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top